Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bradmer Pharmaceuticals has initiated enrollment in the Phase III Glass-Art trial evaluating Neuradiab, a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme.
Subscribe to our email newsletter
The Phase III Glass-Art trial is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), for patients diagnosed with primary glioblastoma mulitforme.
The randomized trial will enroll up to 760 patients at leading treatment centers across the US.
Alan Ezrin, president and CEO of Bradmer, said: “We look forward to bringing this investigational drug to patients via collaborative efforts with more than 30 US cancer centers that are participating in the Glass-Art trial.”